Safety and Biological Activity of Rozibafusp alfa, a Bispecific Inhibitor of Inducible Costimulator Ligand and B Cell Activating Factor, in Patients With Rheumatoid Arthritis: Results of a Phase 1b, Randomized, Double‐Blind, Placebo‐Controlled, Multiple Ascending Dose Study

Safety and Biological Activity of Rozibafusp alfa, a Bispecific Inhibitor of Inducible Costimulator Ligand and B Cell Activating Factor, in Patients With Rheumatoid Arthritis: Results of a Phase 1b, Randomized, Double‐Blind, Placebo‐Controlled, Multiple Ascending Dose Study

Objective To assess the safety and biological activity of rozibafusp alfa, a first‐in‐class bispecific antibody–peptide conjugate targeting inducible costimulator ligand (ICOSL) and B cell activating factor (BAFF), in patients with rheumatoid arthritis (RA). Methods This phase 1b, double‐blind, plac...

Full description

Bibliographic Details
Main Authors: Lubna Abuqayyas, Laurence E. Cheng, Marcia Teixeira dos Santos, Barbara A. Sullivan, Norma Ruiz‐Santiago, Hui Wang, Yanchen Zhou, Vishala Chindalore, Stanley Cohen, Alan J. Kivitz, Maximilian G. Posch, Jane R. Parnes
Format: Article
Language:English
Published: Wiley 2022-10-01
Series:ACR Open Rheumatology
Online Access:https://doi.org/10.1002/acr2.11487

Internet

https://doi.org/10.1002/acr2.11487

Similar Items